| P50 | author | David Dingli | Q66385573 |
| | Jorge M. Pacheco | Q41044325 |
| | Francisco C. Santos | Q41045922 |
| P2860 | cites work | A Quantitative Measurement of the Human Somatic Mutation Rate | Q22065361 |
| | Hallmarks of Cancer: The Next Generation | Q22252312 |
| | Initial genome sequencing and analysis of multiple myeloma | Q24629117 |
| | Cancer genes and the pathways they control | Q28275089 |
| | Mutational landscape and significance across 12 major cancer types | Q28300353 |
| | Mutation selection and the natural history of cancer | Q29614279 |
| | DNA replication fidelity | Q29616841 |
| | Influence of tumour micro-environment heterogeneity on therapeutic response | Q29617534 |
| | Immunological and inflammatory functions of the interleukin-1 family | Q29619669 |
| | (A)symmetric stem cell replication and cancer | Q33279153 |
| | Compartmental architecture and dynamics of hematopoiesis | Q33280998 |
| | Mechanisms of myeloma cell growth control | Q33811572 |
| | Multiple myeloma. | Q34362643 |
| | Multiple myeloma: evolving genetic events and host interactions | Q34624999 |
| | Bone disease in myeloma | Q34678320 |
| | Symmetric vs. asymmetric stem cell divisions: an adaptation against cancer? | Q35034585 |
| | Risk of collective failure provides an escape from the tragedy of the commons | Q35081573 |
| | Consequences of interactions between the bone marrow stroma and myeloma | Q35540078 |
| | New insights into the pathophysiology and management of bone disease in multiple myeloma | Q35591086 |
| | Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS. | Q35623636 |
| | Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo | Q35642745 |
| | Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease | Q43151297 |
| | Reproductive fitness advantage of BCR-ABL expressing leukemia cells | Q43162809 |
| | Role of the bone marrow microenvironment in multiple myeloma | Q44202437 |
| | Evidence that hematopoiesis may be a stochastic process in vivo | Q45876111 |
| | Explaining the in vitro and in vivo differences in leukemia therapy. | Q45958659 |
| | Acquired hematopoietic stem-cell disorders and mammalian size | Q47272839 |
| | Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion | Q47371978 |
| | Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma | Q47965350 |
| | Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. | Q52841131 |
| | Multiple myeloma | Q73386423 |
| | Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma | Q73971509 |
| | Secondary osteoporosis. Diagnostic considerations | Q74787546 |
| | Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma | Q77337118 |
| | Stochasticity and evolutionary stability | Q79199992 |
| | Pathogenesis of myeloma bone disease | Q35683616 |
| | The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression | Q35883830 |
| | Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial | Q36163205 |
| | Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease | Q36169814 |
| | Molecular pathogenesis and a consequent classification of multiple myeloma | Q36254602 |
| | Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma | Q36732811 |
| | Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth | Q36742501 |
| | Myeloma bone disease and proteasome inhibition therapies. | Q36818075 |
| | Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component | Q37148370 |
| | Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells | Q37400506 |
| | Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance | Q37535224 |
| | The use of PIG-A as a sentinel gene for the study of the somatic mutation rate and of mutagenic agents in vivo | Q37662571 |
| | Somatic mutations and the hierarchy of hematopoiesis | Q37783962 |
| | Advances in the biology and treatment of bone disease in multiple myeloma | Q37853737 |
| | Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma | Q40009759 |
| | Routes to repopulation--a unification of the stochastic model and separation of stem-cell subpopulations. | Q40765020 |
| | Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells | Q40821455 |
| P433 | issue | 4 | |
| P921 | main subject | game theory | Q44455 |
| | evolutionary game theory | Q2298789 |
| P6104 | maintained by WikiProject | WikiProject Ecology | Q10818384 |
| P304 | page(s) | 20140019 | |
| P577 | publication date | 2014-08-01 | |
| P1433 | published in | Interface Focus | Q2031916 |
| P1476 | title | The ecology of cancer from an evolutionary game theory perspective | |
| P478 | volume | 4 | |